Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials (Q35784245)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 July 2015

Language	Label	Description	Also known as
English	Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials	scientific article published on 15 July 2015

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

0 references

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

10 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

A Liakos

2

0 references

Thomas Karagiannis

object named as

T Karagiannis

1

0 references

object named as

E Bekiari

3

0 references

Apostolos Tsapas

object named as

A Tsapas

11

0 references

10

object named as

D R Matthews

1 reference

Europe PubMed Central

10 August 2017

author name string

E Athanasiadou

4

1 reference

Europe PubMed Central

10 August 2017

P Paschos

5

1 reference

Europe PubMed Central

10 August 2017

D Vasilakou

6

1 reference

Europe PubMed Central

10 August 2017

M Mainou

7

1 reference

Europe PubMed Central

10 August 2017

M Rika

8

1 reference

Europe PubMed Central

10 August 2017

P Boura

9

1 reference

Europe PubMed Central

10 August 2017

publication date

15 July 2015

1 reference

Europe PubMed Central

10 August 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

10 August 2017

17

1 reference

Europe PubMed Central

10 August 2017

1065-1074

1 reference

Europe PubMed Central

10 August 2017

11

1 reference

Europe PubMed Central

10 August 2017

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

AACE comprehensive diabetes management algorithm 2013.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Do GLP-1-based therapies increase cancer risk?

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noni

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Correlates of health-related quality of life in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12541

21 January 2018

Identifiers

10.1111/DOM.12541

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35784245&oldid=1644817189"